The global mesalamine market size was US$ 169.5 million in 2021. The global mesalamine market size is forecast to reach US$ 212.6 million by 2030, registering a compound annual growth rate (CAGR) of 3.8% during the forecast period from 2022 to 2030.

Mesalamine, also known as Mesalazine, is the first-line agent used to treat active UC. It is a prescription drug that includes 5-aminosalicylic acid. It also helps cure other inflammatory bowel disorders.

Factors Influencing the Market

Mesalamine is considered to be safe, which is why its demand is expected to increase in the coming years. The high prevalence of Ulcerative Colitis (UC) around the world is expected to drive up demand for mesalamine. The market is also likely to grow when new products are released.
The global mesalamine industry is seeing a surge in patient support programs, which will create a slew of new opportunities.
The expansion of the mesalamine market is attributed to the increasing research & development as well as rising spending in healthcare in developing countries.
Side effects of treatments, such as vomiting, fever, headache, stomach, and abdominal discomfort, may limit the growth of the global mesalamine market during the study period.
COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted the global mesalamine market. The demand for pharmaceuticals is forecast to remain the same throughout the COVID-19 pandemic period. Moreover, governments of maximum nations are highly focused on expanding the healthcare expenditure and boosting the healthcare infrastructure. Thus, it will offer ample growth opportunities for market growth. Moreover, companies are highly investing in research and development activities due to the COVID-19 influenced growth. Thus, all of this will contribute to the growth of the global mesalamine market.

Regional Analysis

North America is forecast to hold the largest mesalamine market share due to the growing awareness about the benefits of the drug. In addition, the presence of prominent pharmaceutical firms in the region is forecast to contribute to the market growth. Government funding and incentives are also forecast to surge market growth in the coming years. In addition, the growing prevalence of disease and growing geriatric population will benefit the regional mesalamine market during the study period.

Competitors in the Market

Mylan N.V.
Teva Pharmaceuticals
Ferring B.V.
Allergan
Bausch Health Companies Incorporated (Salix Pharmaceutical).
Zydus Cadila
Cosmo Pharmaceuticals
Tillotts Pharma AG
Shire plc
Pfizer Incorporated
Norga Pharma
AstraZeneca
Abbvie Incorporated
Takeda Pharmaceuticals
Johnson and Johnson
Boehringer Ingelheim GmbH
Sandoz Mesalamine
Cipla
Synmosa Biopharma Corporation
Lunan Better Pharmaceuticals
Merck & Co
Novartis AG
Other Prominent Players
Market Segmentation

The global mesalamine market segmentation focuses on Dosage Form, Application, and Region.

Based on the dosage form, the mesalamine market is segmented into

Capsule
Tablets
Based on application, the mesalamine market is segmented into

Ulcerative colitis
Crohn's disease
Other bowel inflammatory diseases
Based on region, the mesalamine market is segmented into

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America